Want to see SE:SUS full AI Analyst Report?
Surgical Science Sweden AB (SUS) Financial Statements
Surgical Science Sweden AB Financial Overview
Surgical Science Sweden AB's market cap is currently $3.00B. The company's EPS TTM is $1.83; its P/E ratio is 32.16; Surgical Science Sweden AB is scheduled to report earnings on November 12, 2026, and the estimated EPS forecast is $0.68. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 992.34M | $ 884.09M | $ 882.85M | $ 802.54M | $ 366.78M |
| Gross Profit | $ 576.90M | $ 597.90M | $ 612.88M | $ 531.52M | $ 265.94M |
| Operating Income | $ 108.97M | $ 144.32M | $ 189.15M | $ 162.54M | $ 88.75M |
| EBITDA | $ 192.34M | $ 224.29M | $ 324.53M | $ 279.24M | $ 122.27M |
| Net Income | $ 66.82M | $ 131.65M | $ 233.97M | $ 187.97M | $ 86.25M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 616.42M | $ 968.15M | $ 634.37M | $ 433.73M | $ 316.68M |
| Total Assets | $ 4.69B | $ 5.48B | $ 4.70B | $ 4.65B | $ 3.98B |
| Total Debt | $ 78.86M | $ 292.35M | $ 40.02M | $ 14.68M | $ 12.07M |
| Net Debt | $ -537.56M | $ -675.81M | $ -594.34M | $ -419.05M | $ -304.61M |
| Total Liabilities | $ 418.31M | $ 651.03M | $ 357.46M | $ 413.11M | $ 393.06M |
| Stockholders' Equity | $ 4.27B | $ 4.83B | $ 4.35B | $ 4.24B | $ 3.59B |
| Cash Flow | |||||
| Free Cash Flow | $ 68.12M | $ 89.69M | $ 194.16M | $ 94.94M | $ 24.71M |
| Operating Cash Flow | $ 79.80M | $ 137.22M | $ 238.29M | $ 129.49M | $ 39.08M |
| Investing Cash Flow | $ -134.25M | $ -47.53M | $ -44.13M | $ -34.55M | $ -2.73B |
| Financing Cash Flow | $ -259.68M | $ 227.65M | $ 15.85M | $ 17.09M | $ 2.92B |
Currency in SEK